WHO gives further support to Bavarian Nordic and Johnson & Johnson's Ebola vaccine

A WHO committee has updated its recommendations with good news for Johnson & Johnson and Bavarian Nordic's two-dose Ebola vaccine.

Photo: Mads Nissen/STF

The latest recommendations from the World Health Organization (WHO) support the use of Johnson & Johnson and Bavarian Nordic's two-dose vaccine regimen against Ebola virus, according to a Monday press release.

WHO's Strategic Advisory Group of Experts on Immunization (SAGE) has extended its support for the vaccine.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs